https://interactions.guidetherapeutiquevih.com/en/interaction-details?id=6569
https://interactions.guidetherapeutiquevih.com/en/interaction-details?id=6569
No pharmaceutical opinion available for this interaction.
Phenytoin may possibly induce the metabolism and decrease the plasma concentration of Lopinavir / ritonavir.
Lopinavir / ritonavir may possibly induce the metabolism (CYP 2C9) and consequently decrease the concentration of Phenytoin.
Possible decrease of clinical efficacy.
Monitor for signs and symptoms of therapeutic failure.
An increase in dosage may be necessary.
Lopinavir/ritonavir must not be administered once daily in combination with this drug.
–
Possible decrease of clinical efficacy.
Avoid if possible. Use an alternative or monitor patient closely.
Monitor for signs and symptoms of therapeutic failure.
An increase in dosage may be necessary.
As clinically indicated : brivaracetam, gabapentin, lacosamide, lamotrigine, levetiracetam, pregabalin, rufinamide, topiramate, vigabatrin, zonisamide.
–
Lopinavir plasma level
CD4+
Viral load HIV
Phenytoin
| Reference number |
|---|
| # patients |
| HIV |
| Dose |
| Frequency |
| Duration (days) |
| AUC 0-12h |
| C12h |
| Cmax |
| T1/2 |
| AUC 0-24h |
| C24h |
| 1594 |
|---|
| 20 |
| - |
| 400/100 mg |
| BID |
| 1-22 |
| - 33% * |
| - 51% * |
| - 24% * |
| - 50% * |
| 1594 |
|---|
| 20 |
| - |
| 300 mg |
| QHS |
| 11-22 |
| - 28% |
| - 31% |
| - 38% |
Ref #1438: For ritonavir, AUC 0-12h decreased by 28%, Cmax decreased by 20%, C12h decreased by 32%, and T1/2 decreased by 34%.
* Refers to lopinavir.